Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 24-25 Jan 2019, investigators met in Bangkok to launch the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project. Led by MORU and funded by UKaid and the UK Department for International Development (DfID), DeTACT is a large, 14 site trial in 8 African and 5 Asian countries that will study the efficacy, safety and tolerability of two Triple Artemisinin Combination Therapy (TACT) combinations, using combinations of existing antimalarial drugs.

DeTACT group photo

DeTACT will also project the impact of TACTs on controlling the spread or emergence of multi-drug-resistant P. falciparum malaria leading to its elimination, and examine the ethical and commercial considerations of using TACTs across the malaria endemic world.

DeTACT is particularly urgent: strains of P. falciparum malaria parasite highly resistant to artemisinins, our most effective antimalarial drugs, have rapidly spread out of Cambodia and across SE Asia. These malaria ‘superbugs’ have caused a large increase in treatment failures in malaria patients across the Greater Mekong Subregion, and if they emerge in Africa, put millions, especially children under 5, at risk.

“DeTACT is a very important study: Increasing drug resistance in Southeast Asia jeopardizes the treatment of P. falciparum malaria, a potential fatal disease, and malaria elimination is only possible if we have effective drugs to treat the disease,” said Oxford Prof. Arjen Dondorp, Head of Malaria at MORU and principal investigator for DeTACT. “These TACTs can provide an effective and safe malaria treatment, using a combination of already available antimalarial drugs.”

The DeTACT trials will compare two widely used drug combinations (artemether-lumefantrine and arterolane-piperaquine) against two TACTs constituted of one additional drug added to each of these combinations (amodiaquine and mefloquine, respectively).

Based on preliminary results from the recently completed TRACII trials which recruited over 1,000 subjects with uncomplicated falciparum malaria, TACTs already appear to be safe and highly efficacious even against multi-drug resistant falciparum malaria currently prevalent in parts of SE Asia. Before such combinations can be recommended for more widespread use, especially in highly endemic regions of Africa where children are most affected by malaria, their safety and tolerability must be verified.

Stringent assessments to identify cardiac, hepatic, renal or bone marrow toxicity or other study drugs-related dysfunctions will be complemented by predictive mathematical modelling to analyse TACTs’ costs and expected benefits and assess their potential to delay the emergence or spread of drug-resistant P. falciparum malaria.

At the meetings, investigators from the Africa and Asia study sites and researchers leading the complementary work packages and sub-studies presented plans to implement their studies and analyses.

The bioethics component of DeTACT will document patient, practitioner and policy maker views and attitudes on deploying TACTs. It will use focus groups and interviews to identify potential barriers to TACT acceptability and deployment and address ethical issues arising from introducing TACTs to treat African children where current ACT therapy is still efficacious. This work will be supplemented by assessments of the market positioning within and outside donor funded malaria services, and potential market uptake in different malaria epidemiological settings.

Dr Chanaki Amaratunga will jointly coordinate DeTACT with Dr Mehul Dhorda. Chanaki will coordinate the project and focus on the Asia trials and the complementary work packages, while Mehul will coordinate the Africa trials and related activities. DeTACT’s 14 sites include 8 in Africa – the Gambia, Nigeria, Tanzania, Guinea, Niger, Malawi, Burkina Faso and DR Congo – and 6 in Asia – India (2), Cambodia, Bangladesh, Indonesia and Myanmar.

Dr Melanie Renshaw of the African Leaders Malaria Alliance will chair a project steering committee of representatives from the Asia-Pacific Leaders Malaria Alliance, WHO, malaria civil society organisations and academia that will advise the DeTACT management team as it implements activities to make TACTs available to malaria control and elimination campaigns worldwide.

DeTACT is the third of three DfID supported multi-country, multi-site trials (TRAC and TRACII) that have characterised artemisinin resistance and tested multi-drug resistant malaria treatments in SE Asia.

- Thank you, Chanaki Amaratunga and Mehul Dhorda for text and Supa-at (Ice) Asarath for photo

Similar stories

Congratulations Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George

David Warrell, our founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.